Vascular Biogenics reported -10428000 in Net Income for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Net Income Change
Bluebird Bio BLUE:US $ -100.14M 22.01M
Eleven Biotherapeutics EBIO:US $ -0.81M 9.75M
Epizyme EPZM:US $ -35.74M 19.76M
Infinity Pharmaceuticals INFI:US $ -11.99M 0.45M
Newlink Genetics NLNK:US $ -7.72M 2.08M
Prothena PRTA:US $ -41.24M 4.95M
Vascular Biogenics VBLT:US -10428000 1.32M